论文信息 - Evidenced-based medicine in glioma : molecular biology is only part of the story - 字舞流文

Evidenced-based medicine in glioma : molecular biology is only part of the story

R. Guillevin | T. Santarius | H. Duffau | E. Mandonnet | E. D. Witte | A. Grivas | M. Tate | C. Papagno | P. Schucht | S. Sarubbo | D. Satoer | L. Bello | S. Krieg | A. Aerts | G. Rutten | G. Spena | M. Klein | D. Fontaine | A. Rofes | F. Almairac | J. Martino | S. G. Robles | M. Forster | M. Zetterling | M. Wagemakers | M. Polivka | P. D. W. Hamer | J. Pallud | A. Smits | L. Taillandier | P. Robe | E. Visch-Brink | V. Rigau | V. Lubrano | P. Chumas | A. Darlix | H. Colle | M. Baron | F. Rech | J. Goodden | N. Garg | M. Blonski | T. Snijders | C. Freyschlag | G. Campe | Y. Yordanova | M. Wager | F. Barone | C. Viegas | E. Robert | W. Veenstra | Andrés Reyes | M. Ryan | D. Giakoumettis | K. Geemen | Lore Van Brussel | Fleur van Ierschot

[1] G. Reifenberger,et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.

[2] S. Torp,et al. Surgical resection versus watchful waiting in low-grade gliomas , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3] V. Coenen,et al. Residual Tumor Volume as Best Outcome Predictor in Low Grade Glioma – A Nine-Years Near-Randomized Survey of Surgery vs. Biopsy , 2016, Scientific Reports.

[4] H. Duffau,et al. Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas. , 2014, Neuro-oncology.

[5] R. Guillevin,et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. , 2013, Neuro-oncology.

[6] H. Duffau,et al. A new tool for grade II glioma studies: plotting cumulative time with quality of life versus time to malignant transformation , 2011, Journal of Neuro-Oncology.